Terminate Complaining And Initiate Your Very Own ABT-263 Email Campaign Preferably

1). To partly override the baseline between group difference in BMI and triglycerides (Tab. 1), we performed between group comparisons of deltas (��; change between 26th month and baseline) in continuous variables. ��(BMI) (?2.5 �� 1.8 vs. 0.1 �� 1.4; pselleck screening library adverse events, mainly nausea, were transient and clinically non-significant. BMI reduction was observed in exenatide group, whereas BMI remained essentially unchanged in insulin glargine group. Comparable effects were observed in lipid profile in both groups, whereas neither agent had an effect on blood pressure. Other head-to-head studies have provided similar results. In a 26-week, multicenter, open label, randomized trial, exenatide (10 ��g twice daily) reduced HbA1c similarly to insulin glargine (once daily) [9]. Body weight decreased 2.3 kg with exenatide and increased 1.8 kg with insulin glargine. Nocturnal hypoglycemia occurred less frequently Flavoprotein with exenatide, whereas gastrointestinal adverse events, including nausea, vomiting and diarrhea were more common in the exenatide group. In another 16-week multicenter, open-label, randomized, crossover study, treatment with either exenatide (10 ��g twice daily) or insulin glargine (once daily) was associated with similar improvement in HbA1c, independent of treatment order [12], whereas only exenatide therapy was associated with significant reduction in body weight. In another 26-week multicenter, open-label, randomized trial, treatment, either exenatide (10 ��g twice daily) or insulin glargine (once daily) failed to significantly Rapamycin decrease HbA1c. There were more treatment-related adverse events, but lower rate of nocturnal hypoglycaemia and greater efficacy in weight decrease with exenatide [11]. In a more recent 12-month, retrospective study based on a large electronic medical record database, greater reductions in HbA1c and BMI were observed in exenatide compared with insulin glargine-treated patients [10]. There is also a 84-week, multicenter, open label, randomized trial in which insulin glargine was compared to exenatide once weekly [13], which, however, is not currently widely available.